updatepaytience

175 results found.

Top Stocks matching your search for "update paytience"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
HKD

AMTD Digital Inc - ADR

-24.37%

$9.48 - $7.17

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 26, 2023

$HKD the first day hongkong market open go up , hk... See more

Dec, 5, 2022

$HKD Its amazing since august this stock has no m... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 19, 2023

$SLRX great update

Jan, 19, 2023

$SLRX Huge Company with Good Updates and NewsπŸ”₯πŸ”₯πŸ‘‡

HKD

AMTD Digital Inc - ADR

-24.37%

$9.48 - $7.17

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 26, 2023

$HKD the first day hongkong market open go up , hkd$ &AMTD$ flyyyyyyyyy up& update go to the moon , the dream is true

Dec, 5, 2022

$HKD Its amazing since august this stock has no major PR nor CEO updates

Nov, 8, 2022

πŸ‘Œ Deal METAVERSE 100M πŸ‘Œ Deal Nerdland 8M πŸ‘Œ Good news today πŸ‘Œ Update every week on Tuesday!

BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 19, 2023

$SLRX great update

Jan, 19, 2023

$SLRX Huge Company with Good Updates and NewsπŸ”₯πŸ”₯πŸ‘‡

Nov, 10, 2022

$SLRX 'We believe this interim data is an encouraging development for these patients in need of new treatment options and we are looking forward to an additional data update next month.”